NCT06841679 - Utidelone Capsule Combined with Capecitabine and Oxaliplatin in First-line Treatment of PD-L1-negative Gastric or Gastroesophageal Junction Adenocarcinoma Patients | Biotech Hunter

Enrollment

778

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

September 1, 2030

Study Completion Date

September 1, 2030

Conditions

Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Utidelone Capsule

UTD2 40 mg/m2/d, po, qd, day 1-5, q3w

DRUG

Utidelone Capsule

50 mg/m2/d, po, qd, day 1-5, q3w

DRUG

Utidelone Capsule

60 mg/m2/d, po, qd, day 1-5, q3w

DRUG

Capecitabine

1000 mg/m2, po, bid, day 1-14, q3w

DRUG

Oxaliplatin

130 mg/m2/d, iv, day1, q3w, oxaliplatin will be given up to 6 cycles

DRUG

Utidelone Capsule

UTD2 po, on d1-5, q3w (dose decided after the phase II)